Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (171-180 of 240) with videos related to

Pageof 24
Sort By:
Circulation|April 8, 2018
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIERMarc S Sabatine, Gaetano M De Ferrari, Robert P Giugliano, et al.
JAMA Cardiology|May 21, 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER TrialBaris Gencer, François Mach, Sabina A Murphy, et al.
American Heart Journal|March 30, 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategyMarc W Klutstein, Cynthia M Westerhout, Paul W Armstrong, et al.
Journal of the American Heart Association|March 12, 2024
Sustained Pericarditis Recurrence Risk Reduction With Long-Term RilonaceptMassimo Imazio, Allan L Klein, Antonio Brucato, et al.
Journal of the American College of Cardiology|August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 TrialConnie N Hess, Stefan James, Renato D Lopes, et al.
Lancet (London, England)|April 8, 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialSanjit S Jolly, Salim Yusuf, John Cairns, et al.
American Heart Journal|June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAnna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trialsHeinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
Journal of the American Heart Association|December 3, 2015
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialMeena P Rao, Sigrun Halvorsen, Daniel Wojdyla, et al.
Pageof 24

Showing results (171-180 of 240) with videos related to

Sort By:
Pageof 24
Circulation|April 8, 2018
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIERMarc S Sabatine, Gaetano M De Ferrari, Robert P Giugliano, et al.
JAMA Cardiology|May 21, 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER TrialBaris Gencer, François Mach, Sabina A Murphy, et al.
American Heart Journal|March 30, 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategyMarc W Klutstein, Cynthia M Westerhout, Paul W Armstrong, et al.
Journal of the American Heart Association|March 12, 2024
Sustained Pericarditis Recurrence Risk Reduction With Long-Term RilonaceptMassimo Imazio, Allan L Klein, Antonio Brucato, et al.
Journal of the American College of Cardiology|August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 TrialConnie N Hess, Stefan James, Renato D Lopes, et al.
Lancet (London, England)|April 8, 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialSanjit S Jolly, Salim Yusuf, John Cairns, et al.
American Heart Journal|June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trialAnna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 2, 2020
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trialsHeinz Drexel, Basil S Lewis, Giuseppe M C Rosano, et al.
Journal of the American Heart Association|December 3, 2015
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialMeena P Rao, Sigrun Halvorsen, Daniel Wojdyla, et al.
Pageof 24